达沙替尼治疗儿童慢性期慢性髓性白血病:一项II期试验结果
这项II期开放标签非随机前瞻性试验评估达沙替尼治疗113例儿童慢性期慢性髓性白血病(CML-CP)的疗效与安全性,分为伊马替尼耐药/不耐受组与新诊断组。伊马替尼耐药/不耐受组12个月完全细胞遗传学缓解(CCyR)率为76%、主要分子学缓解(MMR)率为41%,新诊断组分别为92%和52%;48个月无进展生存率分别为78%和93%。未报告达沙替尼相关胸腔积液、心包积液、肺水肿或肺动脉高压,4%患者报告骨生长和发育事件。
要点
- 伊马替尼耐药/不耐受组12个月CCyR率76%、MMR率41%,新诊断组CCyR率92%、MMR率52%。
- 伊马替尼耐药/不耐受组48个月无进展生存率78%,新诊断组93%。
- 未报告达沙替尼相关胸腔积液、心包积液、肺水肿或肺动脉高压,4%患者报告骨生长和发育事件。
核心结论
- 在迄今规模最大的儿童CML-CP前瞻性试验中,达沙替尼是安全有效的治疗选择。
- 一线或二线达沙替尼的目标缓解均早期达到,并观察到深度分子学缓解。
- 儿童患者的安全性特征与成人相似,但未报告胸腔积液、心包积液或肺动脉高压病例。
研究设计与样本
- CA180-226/NCT00777036是一项II期、开放标签、非随机前瞻性试验,纳入年龄<18岁的患者。
- 共设三个队列:伊马替尼耐药/不耐受CML-CP;伊马替尼耐药/不耐受加速期/急变期CML或Ph+急性淋巴细胞白血病(n=17);新诊断CML-CP接受片剂或口服混悬液粉末治疗。
- CML-CP患者共113例。
主要发现
- 分析时,伊马替尼耐药/不耐受组14例(48%)和新诊断组61例(73%)仍在治疗中。
- 伊马替尼耐药/不耐受组3个月内达到主要细胞遗传学缓解>30%,新诊断CML-CP组6个月内达到CCyR>55%。
- 12个月时,伊马替尼耐药/不耐受组CCyR率和MMR率分别为76%和41%,新诊断CML-CP组分别为92%和52%。
- 48个月无进展生存率在伊马替尼耐药/不耐受组和新诊断CML-CP组分别为78%和93%。
- 未报告达沙替尼相关胸腔积液、心包积液、肺水肿或肺动脉高压;4%患者报告骨生长和发育事件。
关键数值与推荐
- 伊马替尼耐药/不耐受患者主要细胞遗传学缓解>30%和新诊断患者CCyR>55%为临床关注目标。
- 伊马替尼耐药/不耐受组3个月内达到主要细胞遗传学缓解>30%,新诊断CML-CP组6个月内达到CCyR>55%。
- 12个月CCyR率:伊马替尼耐药/不耐受组76% vs 新诊断CML-CP组92%;MMR率:伊马替尼耐药/不耐受组41% vs 新诊断CML-CP组52%。
- 48个月无进展生存率:伊马替尼耐药/不耐受组78% vs 新诊断CML-CP组93%。
临床怎么用
- 作者结论认为达沙替尼是儿童CML-CP安全、有效的治疗。
- 作者报告一线或二线达沙替尼的目标缓解均早期达到,并观察到深度分子学缓解。
- 作者报告儿童安全性特征与成人相似,但未报告胸腔积液、心包积液或肺动脉高压病例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Safe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I study determined suitable dosing for children with Philadelphia chromosome-positive (Ph+) leukemias. Methods CA180-226/NCT00777036 is a phase II, open-label, nonrandomized prospective trial of patients < 18 years of age receiving dasatinib. There are three cohorts: (1) imatinib-resistant/intolerant CML-CP, (2) imatinib-resistant/intolerant CML in accelerated/blast phase or Ph+ acute lymphoblastic leukemia (n = 17), and (3) newly diagnosed CML-CP treated with tablets or powder for oral suspension. Major cytogenetic response > 30% for imatinib-resistant/intolerant patients and complete cytogenetic response (CCyR) > 55% for newly diagnosed patients were of clinical interest. Results Of 113 patients with CML-CP, 14 (48%) who were imatinib-resistant/intolerant and 61 (73%) who were newly diagnosed remained on treatment at time of analysis. Major cytogenetic response > 30% was reached by 3 months in the imatinib-resistant/intolerant group and CCyR > 55% was reached by 6 months in the newly diagnosed CML-CP group. CCyR and major molecular response by 12 months, respectively, were 76% and 41% in the imatinib-resistant/intolerant group and 92% and 52% in newly diagnosed CML-CP group. Progression-free survival by 48 months was 78% and 93% in the imatinib-resistant/intolerant and newly diagnosed CML-CP groups, respectively. No dasatinib-related pleural or pericardial effusion, pulmonary edema, or pulmonary arterial hypertension were reported. Bone growth and development events were reported in 4% of patients. Conclusion In the largest prospective trial to date in children with CML-CP, we demonstrate that dasatinib is a safe, effective treatment of pediatric CML-CP. Target responses to first- or second-line dasatinib were met early, and deep molecular responses were observed. Safety of dasatinib in pediatric patients was similar to that observed in adults; however, no cases of pleural or pericardial effusion or pulmonary arterial hypertension were reported.
引用
- Gore L, Kearns PR, de Martino ML, et al. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018. PMID: 29498925. doi:10.1200/JCO.2017.75.9597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。